Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one randomized controlled trial. ^[1]
• Lynozyfic (linvoseltamab-gcpt) is indicated for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
• In patients with RRMM treated with linvoseltamab 200 mg, the overall response rate (ORR) was 71%, with a complete response (CR) rate of 50% and a median duration of response (DOR) of 29.4 months (95% CI, 19.2 to not evaluable); 39% of these patients had high-risk cytogenetics and 28% had penta-refractory disease.
• Among patients with RRMM treated with linvoseltamab 200 mg, adverse events included cytokine release syndrome (CRS) (Grade 1: 35.0%, Grade 2: 10.3%, Grade 3: 0.9%), neutropenia (Grade 2: 0.9%, Grade 3: 18.8%, Grade 4: 23.1%), anemia (Grade 1: 3.4%, Grade 2: 4.3%, Grade 3: 30.8%), immune effector cell-associated neurotoxicity syndrome (ICANS) (Grade 1: 2.6%, Grade 2: 2.6%, Grade 3: 2.6%), and infections (overall: 74.4%, Grade 3: 33.3%, Grade 4: 2.6%), with infection frequency and severity declining over time.